Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

548 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group.
Rapold HJ, de Bono D, Arnold AE, Arnout J, De Cock F, Collen D, Verstraete M. Rapold HJ, et al. Among authors: verstraete m. Circulation. 1992 Mar;85(3):928-34. doi: 10.1161/01.cir.85.3.928. Circulation. 1992. PMID: 1537129 Clinical Trial.
Evaluation of the effect of thrombolytic treatment on infarct size and left ventricular function by enzymatic, scintigraphic, and angiographic methods. The European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator.
Mortelmans L, Vanhaecke J, Lesaffre E, Arnold A, Urbain JL, Hermens W, De Roo M, De Geest H, Verstraete M, Van de Werf F. Mortelmans L, et al. Among authors: verstraete m. Am Heart J. 1990 Jun;119(6):1231-7. doi: 10.1016/s0002-8703(05)80169-3. Am Heart J. 1990. PMID: 2112877 Clinical Trial.
Significance of initial ST segment elevation and depression for the management of thrombolytic therapy in acute myocardial infarction. European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator.
Willems JL, Willems RJ, Willems GM, Arnold AE, Van de Werf F, Verstraete M. Willems JL, et al. Among authors: verstraete m. Circulation. 1990 Oct;82(4):1147-58. doi: 10.1161/01.cir.82.4.1147. Circulation. 1990. PMID: 2119263 Clinical Trial.
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
Arnold AE, Brower RW, Collen D, van Es GA, Lubsen J, Serruys PW, Simoons ML, Verstraete M. Arnold AE, et al. Among authors: verstraete m. J Am Coll Cardiol. 1989 Sep;14(3):581-8. doi: 10.1016/0735-1097(89)90096-x. J Am Coll Cardiol. 1989. PMID: 2504798 Free article.
548 results